No Data
Express News | Johnson & Johnson Reports 6.8% Passive Stake in Rapport Therapeutics Inc as of Sept 30- SEC Filing
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Rapport Therapeutics Analyst Ratings
Rapport Therapeutics Initiated With a Buy at JonesResearch
JonesTrading Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $42
Promising Growth and Innovation Drive Buy Recommendation for Rapport Therapeutics, Inc.: Focus on RAP-219 and Strategic Collaborations
No Data
No Data
